Adaptive Biotechnologies is trading 4.3% up today at $23.55 as investors focus on the company’s stronger MRD revenue trajectory and raised full-year guidance.
- The stock is extending its rebound following recent volatility surrounding its July 29 earnings report.
- Sentiment is bolstered by the company's plan to separate its business units to better highlight the high-growth MRD segment.
- The upward move aligns with a broad market risk-on rally, with major U.S. indices gaining more than 1%.